Two Asian pharmaceutical companies are poised to become key players in the global fight against the new coronavirus pandemic after they were tapped to help mass-produce a promising new vaccine for the disease, which has already killed 650,000 worldwide and infected over 16 million.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com